



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/593,119	09/18/2006	Renate Schulze	7601/88256	5922
66991 7590 01/29/2009 LAW OFFICE OF MICHAEL A. SANZO, LLC 15400 CALHOUN DR. SUITE 125 ROCKVILLE, MD 20855				
EXAMINER LEAVITT, MARIA GOMEZ				
ART UNIT		PAPER NUMBER		
1633				
MAIL DATE		DELIVERY MODE		
01/29/2009		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/593,119

Applicant(s)

SCHULZE ET AL.

Examiner

MARIA LEAVITT

Art Unit

1633

Period for Reply -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 18 September 2006.
- 2a) ☐ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 30-47 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☐ Claim(s) _____ is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☒ Claim(s) 30-47 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/CDC)
- 4) ☐ Interview Summary (PTO-413)
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____
- Paper No(s)/Mail Date _____

DETAILED ACTION

Election/Restriction

This application contains the following inventions or groups of inventions, which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

- I. Claim 30, drawn to a **polypeptide** and homologous sequences that have the biological activity of an NAD-or NADP-dependent alcohol dehydrogenase.
- II. Claims 31-36, drawn to an **isolated nucleic acid molecule**, a vector comprising a polynucleotide, and a non human host cells transformed with the vector, said isolated nucleic acid molecule encoding a polypeptide and homologous sequences that have the biological activity of an NAD-or NADP-dependent alcohol dehydrogenase.
- III. Claims 37-40 drawn to a **reaction system** comprising an organic compound which is a substrate of a dehydrogenase, a polypeptide having the biological activity of an NAD-or NADP-dependent alcohol dehydrogenase, a vector comprising a nucleotide sequence encoding said polypeptide, or a nonhuman host comprising said vector and, optionally, a cofactor of the polypeptide.
- IV. Claim 41, drawn to a **process for preparing a polypeptide** having the biological activity of an NAD-or NADP-dependent alcohol dehydrogenase.
- V. Claims 42-44, drawn to a **process producing an organic product compound** which is a product of a dehydrogenase comprising reacting an organic compound which is a substrate of a dehydrogenase with a polypeptide having the biological activity of an NAD-or NADP-dependent alcohol dehydrogenase, a nonhuman host comprising a vector having a nucleotide sequence encoding the polypeptide.

- VI. Claim 45-46, drawn **one or more primers** used for genetic screening of short-chain alcohol dehydrogenases.
- VII. Claim 47, drawn **a Kit** comprising a polypeptide that have the biological activity of an NAD-or NADP-dependent alcohol dehydrogenase, an isolated nucleic acid molecule, a vector comprising a polynucleotide, a non human host cells transformed with the vector and one or more primers used for genetic screening for short-chain alcohol dehydrogenases.

The inventions listed as Groups I-VII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical reasons:

37 CFR 1.475 (c) states:

"If an application contains to more or less than one of the combinations of categories of invention set forth in paragraph (b) of this section, unity of invention might not be present"

37 CFR 1.475 (d) also states:

"If multiple products, processes of manufacture, or uses are claimed, the first invention of the category first mentioned in the claims of the application and the first recited invention of each of the other categories related thereto will be considered as the main invention in the claims, see PCT article 17(3)(a) and 1.476(c)".

The inventions listed as Groups I- VII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical reasons: the technical feature linking groups I-VII appears to be that they all relate to

compositions and methods comprising an isolated polypeptide which have the biological activity of an NAD- or NADP-dependent alcohol dehydrogenase. However, prior art has taught a novel nicotinoprotein (NADH-containing) alcohol dehydrogenase from *Rhodococcus erythropolis* DSM 1069 as an efficient catalyst for coenzyme- independent oxidation of a broad spectrum of alcohols and the interconversion of alcohols (Schenkels et al., Microbiology, 2000, pp. 775-785). Therefore, the technical feature linking the invention of groups I- VII does not constitute a special technical feature as defined by PCT Rule 13.2, as it does not define a contribution over prior art for the reasons set forth above.

The inventions listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Inventions of Groups I- VII are drawn to materially different and distinct inventive concepts, having different chemical structures, physical properties and biological functions. For examples, inventions of Group II, drawn to **an isolated nuclei acid sequence molecule** (e.g., a polynucleotide encoding a polypeptide and homologous sequences that have the biological activity of an NAD-or NADP-dependent alcohol), are structurally and functionally different from inventions of Group I, drawn to a **polypeptide** and homologous sequences that have the biological activity of an NAD-or NADP-dependent alcohol dehydrogenase, as the result of comprising either polynucleotides or polypeptides which require separate searches; they are not obvious variants and deemed patentably distinct for the following reasons: polynucleotides, which are composed of purine and pyrimidine units and polypeptides/proteins, which are composed of amino acids, are structurally distinct molecules; any relationship between a

polynucleotide and polypeptide is dependent upon the information provided by the nucleic acid sequence open reading frame as it corresponds to the primary amino acid sequence of the encoded polypeptide. Moreover, because of the degeneracy of the genetic code, different nucleotide sequences can encode the same polypeptide sequence. Hence, the information provided by a polynucleotide of Group II can be used to make a materially different polypeptide than that of Group I. In addition, inventions of Group III, drawn to **a reaction system**, require an organic compound not disclosed as being required for Groups I and II. Moreover, inventions of Group IV, drawn to **a method for preparing a polypeptide** that have the biological activity of an NAD-or NADP-dependent alcohol dehydrogenase, require the step of growing a non-human host cell transformed with a vector encoding a polypeptide that have the biological activity of an NAD-or NADP-dependent alcohol dehydrogenase which is not required by the inventions of Groups I, II and III. Furthermore, inventions of Group V, drawn to **a process producing an organic product compound**, requires the step of reacting an organic compound which is a substrate of a dehydrogenase with a polypeptide having the biological activity of an NAD-or NADP-dependent alcohol dehydrogenase which is not disclosed as being required for Groups I, II, III and IV. Moreover, inventions of Groups VI and VIII are drawn to a single general inventive concept that lacks the same or corresponding special technical features. For example, the kit of Group VII comprises comprising a polypeptide that has the biological activity of an NAD-or NADP-dependent alcohol dehydrogenase, an isolated nucleic acid molecule, a vector comprising a polynucleotide, a non human host cells transformed with the vector and one or more primers used for genetic screening for short-chain alcohol dehydrogenases.

The claims in Groups I- VII are drawn to distinct products and methods that utilize distinct steps, requiring non-coextensive search and examination. Thus, it follows from the preceding analysis that the claimed inventions listed as Groups I- VII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding technical features for the reasons set forth above.

In addition, if any of inventions **I, II, III, IV, V, or VII** are elected, a **further restriction** is required between nucleotide sequences and the corresponding proteins sequences which involve nucleic acid molecules of **SEQ ID NO: 1 to SEQ ID NO: 34** as recited in claim 30, which are each distinct nucleic acid molecules of sequences which encode specific and unique polypeptides. The inventions listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: As the technical feature of a nucleotide sequence coding for a polypeptide, linking the members does not constitute a special technical feature as defined by PCT Rule 13.2, particularly since each of the each nucleic acid does not overlap in scope with the others, are not obvious variants, and have materially different functions, the requirement for unity of invention is not fulfilled. **Applicants must elect one specific nucleotide SEQ ID NO encoding a corresponding polypeptide sequence.**

MPEP 1893.03(d) states:

If an examiner (1) determines that the claims lack unity of invention and (2) requires election of a single invention, when all of the claims drawn to the elected invention are allowable (i.e., meet the requirements of 35 U.S.C. 101, 102, 103 and 112), the nonelected invention(s) should be considered for rejoinder. Any nonelected product claim that requires all the limitations of an allowable product claim, and any nonelected process claim that requires all the limitations of an allowable process claim, should be rejoined. See MPEP § 821.04 and §

821.04(a). Any nonelected processes of making and/or using an allowable product should be considered for rejoinder following the practice set forth in MPEP § 821.04(b).

Species restriction

Should **Group II** be elected, a species restriction is further required under 35 U.S.C. 121 and 372, wherein a species election(s) must correspond to an elected group as indicated above. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

1) a cell, a transgenic animal, as recited in claim 34.

The species are independent or distinct because there are non-human hosts having different chemical structures, physical properties, and biological functions. For example, a transgenic animal is generally a multicellular organism rather than a single-celled with an organized complex structure, and having the capacity for spontaneous movement and rapid motor responses to stimulation. The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: As the technical feature of a non-human host, linking the members do not constitute a special technical feature as defined by PCT Rule 13.2, particularly since each of the species does not share a substantially common structural feature, the requirement for unity of invention is not fulfilled.

Should **Group III** be elected, a species restriction is further required under 35 U.S.C. 121 and 372, wherein a species election(s) must correspond to an elected group as indicated above. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

2) a carbonyl compound, an alcohol, aldehyde, a ketone, a primary alcohol, a chiral secondary alcohol, an asymmetrically substituted ketone, as recited in claims 38, 39 and 40

The species are independent or distinct because there are substrates of a dehydrogenase having different chemical structures, physical properties, and biological functions. The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: As the technical feature of a substrate of a dehydrogenase, linking the members do not constitute a special technical feature as defined by PCT Rule 13.2, particularly since each of the species does not share a substantially common structural feature, the requirement for unity of invention is not fulfilled.

3) NADH, NADPH, NAD⁺ or NADP⁺, as recited in claim 38.

The species are independent or distinct because there are cofactors having different chemical structures, physical properties, and biological functions. The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: As the technical feature of a cofactor, linking the members do not constitute a special technical feature as defined by PCT Rule 13.2, particularly since each of the species does not share a substantially common structural feature, the requirement for unity of invention is not fulfilled.

Should **Group VI** be elected, a species restriction is further required under 35 U.S.C. 121 and 372, wherein a species election(s) must correspond to an elected group as indicated above.

These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

4) one specifically named primer from the group presented in **Table 1**, as recited in claim 47.

The species are independent or distinct because there are **oligonucleotides** having different chemical structures, physical properties, and biological functions.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: As the technical feature of a nucleotide sequence, linking the members does not constitute a special technical feature as defined by PCT Rule 13.2, particularly since each of the each nucleic acid does not overlap in scope with the others, are not obvious variants, and have materially different functions, the requirement for unity of invention is not fulfilled.

Applicant is required, in reply to this action, to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, at least claims 30, 31, 37 and 42 are generic.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species to be examined even though the requirement may be traversed (37 CFR 1.143) **and identification of the claims encompassing the elected species**, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

The election of the species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the election of species requirement, the election shall be treated as an election without traverse. Traversal must be presented at the time of election in order to be considered timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable on the elected species.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the species unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other species.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Maria Leavitt whose telephone number is 571-272-1085. The examiner can normally be reached on M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph Woitach, Ph.D can be reached on (571) 272-0739. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Group Art Unit 1633; Central Fax No. (571) 273-8300. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

/Maria Leavitt/

Maria Leavitt, Ph.D.
Examiner, Art Unit 1633